Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

Impact · against what's priced in

XBIO receives a positive catalyst as its collaboration partner gains regulatory approval to move DNase I into a clinical study for large B-cell lymphoma. The move from preclinical models to human patients in a high-unmet-need population represents a meaningful value inflection point.

XBIO+0.60

No priced-in read yet